How newer bispecifics, including teclistamab & talquetamab, may influence myeloma treatment
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the potential of bispecific antibodies in multiple myeloma, specifically highlighting the interest in the use of teclistamab and talquetamab in the newly diagnosed setting. Dr Ramasamy also discusses promising results observed in ongoing trials with these agents. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
